Difference between revisions of "Timeline of lymphoma"

This is a '''timeline of [[lymphoma]]''', describing especially major discoveries and advances in treatment against the disease.

|19th Century||The presence of lymphoma in western medical literature is born after the works of people like [[Thomas Hodgkin]] and [[Samuel Wilks]]. [[Hodgkin's lymphoma]] is the first lymphoma to be described.

|1900–1950s||It is found that radiation therapy can cure some patients with Hodgkin lymphoma, one of two major classes of lymphomas. When it is discovered that radiating larger parts of the body improves cure rates, physicians begin increasing the size of the radiation fields. [[Radiotherapy]] starts to prove successful as a treatment against Hodgkin's lymphoma in the 1940s.<ref name="newsmedical" /> However, long-term effects of radiation to the chest (including cardiovascular disease and second cancers) are later recognized, and efforts start to be taken to reduce radiation exposure to healthy tissue.<ref name="cancerprogress">{{cite web|title=Progress & Timeline|url=http://cancerprogress.net/timeline/lymphoma|accessdate=23 August 2016}}</ref>

|1960s–1970s||Very effective treatments for [[Hodgkin's lymphoma]] are developed in this period.<ref>{{cite web|title=Lymphoma - Hodgkin - Treatment Options|url=http://www.cancer.net/cancer-types/lymphoma-hodgkin/treatment-options|accessdate=25 August 2016}}</ref> Chemotherapeutic agents are combined into regimens capable of eradicating and even disseminating the disease.<ref name=ascopubs>{{cite web|title=Hodgkin’s Lymphoma: The Hazards of Success|url=http://jco.ascopubs.org/content/21/18/3388.full|accessdate=25 August 2016}}</ref> Combination of chemotherapy and high-energy radiation therapy are introduced.<ref>{{cite journal|title=Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma|doi=10.1056/NEJMoa1505949|url=http://www.nejm.org/doi/full/10.1056/NEJMoa1505949?rss=mostViewed#t=article | volume=373|journal=New England Journal of Medicine|pages=2499–2511}}</ref>

|1666||Development||Italian biologist [[Marcello Malpighi]] publishes ''De viscerum structuru exercitatio anatomica'', where he describes what later will be known as [[Hodgkin's lymphoma]].<ref name="Lakhtakia">{{cite journal|title=A Historical Tale of Two Lymphomas|pmc=4450782 | pmid=26052452 | volume=15|year=2015|journal=Sultan Qaboos Univ Med J|pages=e202–6 | last1 = Lakhtakia | first1 = R | last2 = Burney | first2 = I}}</ref>||

|1832||Development||British physician [[Thomas Hodgkin]] presents a paper describing seven patients with painless enlargement of the [[lymph node]]s, and including [[autopsy]] findings and illustrations from one of the patients.<ref name="Lakhtakia" />||[[London]], [[United Kingdom]]

|1856||Book||British physician [[Samuel Wilks]] publishes ''Cases of lardaceous diseases and some allied affections with remarks'', describing similar cases to those presented by [[Thomas Hodgkin]]. Wilks honors Hodgkin by [[eponym]]ously referring to this disease as ''Hodgkin's lymphoma''.<ref name="Lakhtakia" />||

|1871||Development||Billroth reports the first case of [[non-Hodgkin's lymphoma]]<ref name=pollock>{{cite book|last1=Pollock|first1=Raphael|title=Advanced Therapy in Surgical Oncology|page=236|url=https://books.google.com.ar/books?id=_ZiBwOH_BS8C&pg=PA236&lpg=PA236&dq=%22billroth%22+%22lymphoma%22&source=bl&ots=5YByxfAQZc&sig=v40ua5NzyKFCXvBQftDC0qIBvmE&hl=en&sa=X&ved=0ahUKEwjGuOW5m9jOAhVFGZAKHZ70DZIQ6AEIKTAD#v=onepage&q=%22billroth%22%20%22lymphoma%22&f=false}}</ref>

|1878||Development||W. S. Greenfield first publishes drawings of the [[pathognomonic]] giant cells, later called [[Reed–Sternberg cell]]s.<ref>{{cite book|last1=Hoffman|first1=Ronald|title=Hematology: Basic Principles and Practice, Expert Consult Premium Edition|page=1138|pages=|url=https://books.google.com.ar/books?id=M5fD7gZSDYMC&pg=PA1138&lpg=PA1138&dq=%221878%22+%22Greenfield%22+Hodgkin%22&source=bl&ots=DATR_dxEi7&sig=e0YVRIaenfqKBhmLOehGsuxPh3E&hl=en&sa=X&ved=0ahUKEwjtooOqk9bOAhVLgpAKHVBNDTIQ6AEIKTAD#v=onepage&q=%221878%22%20%22Greenfield%22%20Hodgkin%22&f=false}}</ref>||

|1894||Development||Osler first mentions use of [[chemotherapy]] for lymphoma in his work ''Textbook of Medicine''.<ref>{{cite book|last1=Specht|first1=Lena|title=Radiotherapy for Hodgkin Lymphoma|page=45|url=https://books.google.com.ar/books?id=NJqVQVVd7dQC&pg=PA45&lpg=PA45&dq=%221894%22+%22Osler%22+%22lymphoma%22&source=bl&ots=kn7WK52u11&sig=GYdAvlDu8Qwkd6yzv42lWWYztKY&hl=en&sa=X&ved=0ahUKEwiHmpipmNbOAhVHlpAKHcTsDrkQ6AEIIzAB#v=onepage&q=%221894%22%20%22Osler%22%20%22lymphoma%22&f=false}}</ref>||

|1898||Development||Austrian pathologist [[Carl Sternberg]] first describes in detail giant cells ([[Reed–Sternberg cell]]s).<ref name="lymphomainfo">{{cite web|title=Hodgkin's Disease - Historical Timeline|url=http://www.lymphomainfo.net/hodgkins/timeline.html|accessdate=22 August 2016}}</ref>||[[Germany]]  

|1902||Development||American physician [[Dorothy Reed Mendenhall]] independently describes Reed-Sternberg cells.<ref name="lymphomainfo" />||[[United States]]

|1910||Discovery||Albert Cook, a missionary doctor in [[Africa]], reports a child with a large jaw tumor, in what becomes the first description of [[Burkitt lymphoma]].<ref>{{cite book|last1=Robertson|first1=Erle S.|title=Burkitt’s Lymphoma|page=1|url=https://books.google.com.ar/books?id=qgPl0rdoE8UC&pg=PA1&lpg=PA1&dq=%22lymphoma%22+%22first+description%22&source=bl&ots=LWWKA-shQ3&sig=RVeNerpiYqlzYqZyEPyIbJsutm8&hl=en&sa=X&ved=0ahUKEwiO-9qjpt3OAhWLHZAKHTOlCdYQ6AEIPjAE#v=onepage&q=%22lymphoma%22%20%22first%20description%22&f=false}}</ref>||[[Uganda]]

|1925||Discovery||[[Follicular lymphoma]] is first described.<ref>{{cite journal|title=Follicular lymphoma: a historical overview.|doi=10.1080/10428190601059746|pmid=17325883 | volume=48|journal=Leuk Lymphoma|pages=232-43 | last1 = van Besien | first1 = K | last2 = Schouten | first2 = H}}</ref>||

|1932||Development||Chevalier and Bernard describe the use of [[radiation therapy]] to treat Hodgkin's disease.<ref name="newsmedical">{{cite web|title=Hodgkin's Lymphoma History|url=http://www.news-medical.net/health/Hodgkins-Lymphoma-History.aspx|accessdate=22 August 2016}}</ref>||

|1944||Discovery||[[Lymphoplasmacytic lymphoma]], also known as Waldenström's macroglobulinemia, is first described by Swedish oncologist [[Jan G. Waldenström]].<ref>{{cite journal|title=Waldenström's Macroglobulinemia — Clinical and Pathological Report of a Case Resembling Multiple Myeloma|doi=10.1056/NEJM195806262582604|url=http://www.nejm.org/doi/full/10.1056/NEJM195806262582604 | volume=258|journal=New England Journal of Medicine|pages=1293–1296}}</ref>||[[Sweden]]

|1949||Treatment||First [[chemotherapy]] drug ([[nitrogen mustard]]) is approved by the [[Food and Drug Administration]] (FDA) for the treatment of Hodgkin's lymphoma.<ref name="cancerprogress" />||United States  

|1949–1956||Discovery||After shielding a mouse's [[spleen]], researchers discover that the body recruits [[stem cell]]s, which are found in the spleen and [[bone marrow]], to protect and heal itself from [[radiation damage]].<ref name="cancerprogress" />||

|1956||Development||American chemist [[Henry Rapoport]] proposes the first classification of [[non-Hodgkin's lymphoma]] based on cellular morphology.<ref name="pollock" />||

|1963||Treatment||First program for combination of chemotherapy agents against Hodgkin's lymphoma is designed, combining [[cyclophosphamide]], [[vincristine]], [[methotrexate]], and [[prednisone]] (MOMP).<ref>{{cite book|last1=Heinz|first1=Beverley|title=Trends in Hodgkin's Disease Research|url=https://books.google.com.ar/books?id=wDS_iYHWq40C&pg=PA77&lpg=PA77&dq=%221963%22+%22cyclophosphamide%22+%22vincristine%22+%22methotrexate%22&source=bl&ots=zZO1VRAwCt&sig=Tx1v6h_zPHEbpgjkHuW6iXB5CRY&hl=en&sa=X&ved=0ahUKEwjz9r2_qdbOAhXHi5AKHXzFAN0Q6AEIJzAB#v=onepage&q=%221963%22%20%22cyclophosphamide%22%20%22vincristine%22%20%22methotrexate%22&f=false}}</ref>||

|1965||Organization||The [[International Agency for Research on Cancer]] (IARC) is founded as an intergovernmental agency forming part of the [[World Health Organization]] of the [[United Nations]]. Its role is to conduct and coordinate research into the causes of cancer.<ref>{{cite web|title=International Agency for Research on Cancer|url=http://www-dep.iarc.fr/|accessdate=28 August 2016}}</ref>||[[Lyon]], [[France]]

|1966||Discovery||It is discovered that Hodgkin's lymphoma spreads through the body in an orderly and somewhat predictable way. This implies that [[prognosis]] and appropriate treatment can be determined based on the extent of the spread.<ref name="cancerprogress" />||

|1967||Treatment||New chemotherapy regimen called MOPP ([[mechlorethamine]], [[vincristine]], [[procarbazine]] and [[prednisone]]) is found to cure more than 50 percent of patients with advanced [[Hodgkin's lymphoma]].<ref name="cancerprogress" />||  

|1974||Treatment||Antibiotic [[doxorubicin]] is approved by [[FDA]] as part of combination chemotherapy against [[Hodgkin's lymphoma]].<ref name="cancerprogress" />||United States   

|1975||Discovery||Researchers first identify [[lymphoblastic lymphoma]].<ref name="onlinelibrary.wiley.com">{{cite web|title=Historical review of lymphomas|url=http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2141.2000.01988.x/full|accessdate=23 August 2016}}</ref>||

|1975||Treatment||New chemotherapy combination of [[doxorubicin]], [[bleomycin]], [[vinblastine]],  and [[dacarbazine]] (known as ABVD) is found to be more effective than the older MOPP combination regimen, and causes fewer side effects.<ref name="cancerprogress" />||

|1977||Discovery||[[Adult T-cell leukemia/lymphoma]], a distinct subtype of lymphoma, is reported.<ref name="onlinelibrary.wiley.com" />||[[Japan]]

|1983||Discovery||[[MALT lymphoma]] is first described by Isaacson and Wright.<ref>{{cite journal|title=Molecular Pathogenesis of MALT Lymphoma|pmc=4397421|pmid=25922601|doi=10.1155/2015/102656|volume=2015|year=2015|journal=Gastroenterol Res Pract|pages=102656 | last1 = Troppan | first1 = K | last2 = Wenzl | first2 = K | last3 = Neumeister | first3 = P | last4 = Deutsch | first4 = A}}</ref>||

|1985||Treatment||[[Bone marrow]] transplantation is successfully used to cure lymphoma.<ref name="cancerprogress" />||

|1987||Discovery||[[Epstein-Barr virus]] (EBV) [[DNA]] is first reported in [[Reed–Sternberg cell]]s of a proportion of [[Hodgkin's lymphoma]] cases.<ref name="Lakhtakia"/>||

|1990||Organization||The [[International Lymphoma Study Group]] is founded.<ref name="Lakhtakia"/>||

|1991||Organization||[[Lymphoma Research Foundation of America]] (LRFA) is founded.<ref name="lymphomainfo"/>||[[Los Angeles]], United States

|1992||Discovery||[[Mantle cell lymphoma]] subtype is first recognized.<ref>{{cite web|title=Aggressive Non-Hodgkin's Lymphoma (Mantle Cell Lymphoma) On The Rise|url=https://www.sciencedaily.com/releases/2008/07/080707081821.htm|accessdate=25 August 2016}}</ref>||

|1992||Treatment||German Hodgkin Study Group (GHSG) develops the BEACOPP regimen for patients with advanced Hodgkin's lymphoma, involving the use of chemotherapy agents [[bleomycin]], [[etoposide]], [[adriamycin]], [[cyclophosphamide]], [[oncovin]], [[procarbazine]] and [[prednisone]].<ref name="newsmedical" /><ref>{{cite journal|last1=Diehl|first1=V|title=Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma (HL)?|doi=10.1080/07357900600981380|pmid=17118782|volume=24|journal=Cancer Invest|pages=713-7}}</ref>||[[Germany]]  

|1994||Development||The Revised European-American Classification of Lymphoid Neoplasms (REAL) is proposed as a new classification for [[non Hodgkin's lymphoma]], taking into account immunologic, genetic and clinical characteristics of the disorders in addition to [[histopathologic]] characteristics of the tumor cells.<ref name="non-hodgkin">{{cite web|title=Non-Hodgkin Lymphoma History|url=http://www.news-medical.net/health/Non-Hodgkin-Lymphoma-History.aspx|accessdate=23 August 2016}}</ref>||  

|1994||Organization||[[Cure for Lymphoma Foundation]] is established.<ref name="lymphomainfo"/>||[[New York City]], United States

|1994||Discovery||[[Primary effusion lymphoma]] type is first recognized.<ref>{{cite web|title=Primary Effusion Lymphoma|url=http://www.knowcancer.com/oncology/primary-effusion-lymphoma/|accessdate=25 August 2016}}</ref>||

|1995||Discovery||Researchers discover that [[lymphocyte]] transfusion from a biologically matched, healthy donor to a patient with [[chronic myelogenous leukemia]] can induce the disease into remission.<ref name="cancerprogress"/>||

|1997||Treatment||[[FDA]] approves [[rituximab]], the first molecularly targeted cancer drug, to treat patients with B-cell non-Hodgkin lymphoma that no longer responds to other treatments<ref>{{cite journal|title=Rituximab|pmid=11467356 | volume=1 | journal=Curr Pharm Biotechnol|pages=1-9 | last1 = Grillo-López | first1 = AJ | last2 = White | first2 = CA | last3 = Dallaire | first3 = BK | last4 = Varns | first4 = CL | last5 = Shen | first5 = CD | last6 = Wei | first6 = A | last7 = Leonard | first7 = JE | last8 = McClure | first8 = A | last9 = Weaver | first9 = R | last10 = Cairelli | first10 = S | last11 = Rosenberg | first11 = J}}</ref>||United States

|1997||Discovery||[[ALK+ large B-cell lymphoma]] is first reported.<ref>{{cite journal |authors=Morgan EA, Nascimento AF |title=Anaplastic lymphoma kinase-positive large B-cell lymphoma: an underrecognized aggressive lymphoma |journal=Adv Hematol |volume=2012 |issue= |pages=529572 |year=2012 |pmid=22474449 |pmc=3299366 |doi=10.1155/2012/529572 }}</ref>||

|2002||Treatment||[[FDA]] approves [[ibritumomab tiuxetan]], which combines radioactive material with a specific [[protein]].  The radioactive material kills the cells with which it comes in contact, while sparing the healthy surrounding tissue. It is the first [[radioimmunotherapy]] introduced to treat lymphoma.<ref name="cancerprogress" />||United States  

|2008||Discovery||WHO classification recognizes [[primary mediastinal (thymic) large B cell lymphoma]] type.<ref>{{cite book |first1=Steven H. |last1=Swerdlow |author2=International Agency for Research on Cancer |author3=World Health Organization |title=WHO classification of tumours of haematopoietic and lymphoid tissues |url=http://apps.who.int/bookorders/anglais/detart1.jsp?codlan=1&codcol=70&codcch=4002 |year=2008 |publisher=International Agency for Research on Cancer |edition=4th | volume=2 |series=World Health Organization classification of tumours |isbn=9789283224310}}</ref><ref>{{Cite book | last=Jaffe | first=ES | author2=Harris NL | author3=Vardiman JW | author4=Campo E | author5= Arber DA|title=Hematopathology | publisher=Elsevier Saunders| year=2011 | chapter=|edition=1st |isbn= 9780721600406}}</ref>||

|2013–2014||Drug||[[Ibrutinib]] is approved by the [[FDA]] for patients with [[mantle cell lymphoma]] or [[chronic lymphocytic leukemia]] that progresses despite other standard therapies.<ref name="cancerprogress" />||United States

* [[Timeline of leukemia]]

* [[Timeline of lung cancer]]

* [[Timeline of melanoma]]

* [[Timeline of brain cancer]]

[[Category:Lymphoma]]

[[Category:Health-related timelines]]